Schroder Investment Management Group
ENTA icon

Schroder Investment Management Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Schroder Investment Management Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-29,652
Closed -$654K – 1151
2016
Q2 		$654K Sell
29,652
-12,164
-29% -$318K ﹤0.01% 951
2016
Q1 		$1.19M Sell
41,816
-397,487
-90% -$11.1M ﹤0.01% 894
2015
Q4 		$14.5M Buy
439,303
+210,303
+92% +$6.85M 0.03% 548
2015
Q3 		$8.28M Sell
229,000
-24,278
-10% -$1.04M 0.02% 641
2015
Q2 		$11M Buy
253,278
+239,500
+1,738% +$9.32M 0.02% 616
2015
Q1 		$432K Buy
+13,778
New +$536K ﹤0.01% 1013

Other funds holding ENTA

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Schroder Investment Management Group's ENTA Position: Q3 2016 in Review

Schroder Investment Management Group sold out of Enanta Pharmaceuticals (ENTA) in Q3 2016, closing a stake of 29,652 shares — an estimated $654K sold.

Schroder Investment Management Group first reported a position in ENTA in Q1 2015 and held it in 6 quarters. The position peaked at $14.5M in Q4 2015. 136 funds tracked by Wall St. Rank hold ENTA as of Q3 2016.

  • Schroder Investment Management Group reported no remaining Enanta Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Schroder Investment Management Group sold 29,652 Enanta Pharmaceuticals shares in Q3 2016, an estimated $654K.
  • Schroder Investment Management Group first reported a position in Enanta Pharmaceuticals in Q1 2015 and held it in 6 quarters.
  • Schroder Investment Management Group's Enanta Pharmaceuticals position peaked at $14.5M in Q4 2015.
  • 136 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2016.

Based on Schroder Investment Management Group's 13F filing for Q3 2016, filed 9 Nov 2016.